NCT00189514 - A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Obesity

Interventions

DRUG

pramlintide acetate

Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg

DRUG

placebo

subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate

Trial Locations (21)

Research Site, Chula Vista

Research Site, San Diego

Research Site, Walnut Creek

Research Site, Miami

Research Site, Augusta

Research Site, Chicago

Research Site, Indianapolis

Research Site, Overland Park

Research Site, Baton Rouge

Research Site, Detroit

Research Site, Edina

Research Site, St Louis

Research Site, Butte

Research Site, New York

Research Site, Cincinnati

Research Site, Portland

Research Site, Philadelphia

Research Site, Austin

Research Site, San Antonio

Research Site, Salt Lake City

Research Site, Olympia